Spherix Global Insights

September 14, 2021

Biohaven’s Ambitious Nurtec ODT Marketing Strategy Pays Dividends With Doctors in Migraine Market: Analyst

From: FiercePharma

By: Beth Snyder Bulik

Chiasma secures FDA approval for acromegaly pill Mycapssa years after near-catastrophic rejection | LifeSci Communications


Biohaven went all-in on marketing its added preventative indication for oral migraine med Nurtec. And now it’s reaping the rewards with doctors. Three months post-approval, 96% of neurologists were aware of the brand, while 65% are “highly familiar” with it, according to Spherix Global Insights’ postlaunch report…(read more)